Monoclonal Antibody Development

We have developed a pipeline for rapid flow cytometry and cell-sorting-based development of either mouse or human monoclonal antibodies with potential uses as research tools or therapies.

Human T-lymphotropic virus 1 (HTLV-1) and Adult T cell Leukemia/Lymphoma (ATLL)
We have interests in the development of therapies for treatment of HTLV-1 and ATLL using basic research principles and structural biological approaches.

Understanding the impacts of vaccine adjuvants on immune responses
We have interests in characterising the impacts that specific antigen/adjuvant pairings have in vaccine development, and how this understanding can guide adjuvant selection in vaccine development

The structural basis for anti-retroviral efficacy for novel indications
We have interest in understanding the applicability and potential efficacy of existing and novel anti-retroviral therapies for treatment of different retroviral infections. Our current focuses are on HTLV-1 and Koala Retrovirus.

Qualifications

  • Doctor of Philosophy, The University of Queensland
  • Bachelor of Biomedical Science (Honours), The University of Queensland
  • MBA

    Publications

    See full publications list.

    Featured projects Duration
    Rapid Response Vaccine Pipeline
    20192026
    Preclinical Development of a vaccine for HTLV-1
    20192026
    KORV
    20072027